The value of immunohistochemistry as a diagnostic aid in gynaecological pathology

Progress in Pathology: Volume 7

Volumn , Issue , 2007, Pages 73-100

  McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926080744     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545955.005     Document Type: Chapter

References (184)

1. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 2002; 40: 309-26.
2. McCluggage WG. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 2000; 53: 327-34.
3. Yaziji H, Gown AM. Immunohistochemical analysis of gynaecologic tumors. Int J Gynecol Pathol 2001; 20: 64-78.
4. Lash RH, Hart WR. Intestinal adenocarcinomas metastatic to the ovaries: A clinicopatho-logic evaluation of 22 cases. Am J Surg Pathol 1989; 11: 114-21.
5. Wauters CCAP, Smedts F, Gerrits LGM et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995; 26: 852-55.
6. Lagendijk JA, Mullink H, van Diest PJ et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry. Differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998; 29: 491-7.
7. Berezowski K, Stasny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996; 9: 426-9.
8. Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol 1996; 9: 1040-4.
9. Ueda G, Sawada M, Ogawa H et al. Immunohistochemical study of cytokeratin 7 for the differentiated diagnosis of adenocarcinoma in the ovary. Gynecol Oncol 1993; 51: 219-23.
10. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40: 403-9.
11. Park SO, Kim HS, Hong EK, Kim AWH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002; 33: 1078-85.
12. Cathro HP, Stoler MH. Expression of cytokeratin 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002; 117: 944-51.
13. Multhaupt HA, Arenas-Elliott CP, Warhol MJ. Comparison of glycoprotein expression between ovarian and colonic adenocarcinomas. Arch Pathol Lab Med 1999; 123: 909-16.
14. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colon and breast origin. Comparison between a statistical and intuitive approach. J Clin Pathol 1999; 52: 283-90.
15. DeCostanzo DC, Elias JM, Chumas JC. Necrosis in 84 ovarian carcinomas: A morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochem-ical analysis of cytokeratin subtypes and carcinoembryonic antigen. Int J Gynecol Pathol 1997; 16: 245-9.
16. Young RH, Wart WR. Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary: A report of seven cases. Am J Surg Pathol 1989; 13: 748-56.
17. Young RH, Scully RE. Ovarian metastases from carcinoma of the gallbladder and extrahepatic bile ducts simulating primary tumors of the ovary: A report of six cases. Int J Gynecol Pathol 1990; 9: 60-72.
18. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: Gross and histologic features in 50 cases. Am J Surg Pathol 2003; 27: 281-92.
19. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology 2003; 42: 137-40.
20. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc 4 and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002; 21: 391-400.
21. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001; 116: 246-52.
22. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan S. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol 2000; 31: 672-7.
23. Young RH, Hart WR. Renal cell carcinoma metastatic to the ovary: A report of three cases emphasizing possible confusion with ovarian clear cell adenocarcinoma. Int J Gynecol Pathol 1992; 11: 96-104.
24. Young RH, Hart WR. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma: A clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol 1998; 22: 805-15.
25. Cameron RI, Ashe P, O'Rourke DM, Foster H, McCluggage WG. A panel of immunohis-tochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 2003; 22: 272-6.
26. Guerrieri C, Franlund B, Fristedt S et al. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei. Histogenetic implications of cytokeratin 7 expression. Hum Pathol 1997; 28: 1039-45.
27. Ronnett BM, Shmookler BM, Diener-West M et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997; 16: 1-9.
28. Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature teratomas: Relationship to pseudomyxoma peritonei. Mod Pathol 2003; 16: 209A.
29. O'Connell JT, Hacker CM, Barsky SH. MUC2 is a molecular marker for pseudomyxoma peritonei. Mod Pathol 2002; 15: 958-72.
30. Clement PB, Young RH, Scully RE. Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol 1996; 20: 1067-80.
31. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998; 22: 1203-14.
32. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002; 40: 237-44.
33. Khoury N, Raju U, Crissman JD, Zarbo RJ, Greenawald KA. A comparative immunohis-tochemical study of peritoneal and ovarian serous tumors and mesotheliomas. Hum Pathol 1990; 21: 811-19.
34. Goldstein NS, Uzieblo A. WT-1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002; 117: 541-5.
35. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109-15.
36. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000; 19: 158-63.
37. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fugii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999; 85: 669-77.
38. Young RH, Scully RE. Ovarian sex cord-stromal tumors: Problems in differential diagnosis. Pathol Annu 1998; 23: 237-96.
39. McCluggage WG, Maxwell P, Sloan JM. Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin. Hum Pathol 1997; 28: 1034-8.
40. Zheng W, Sung CJ, Hanna I et al. A and b subunits of inhibin/activin as sex cord-stromal differentiation markers. Int J Gynecol Pathol 1997; 16: 263-71.
41. Stewart CJR, Jeffers MD, Kennedy A. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumours and their histological mimics. Histopathology 1997; 31: 67-74.
42. Hildebrandt RH, Rouse RV, Longacre TA. Value of inhibin in the identification of granulosa cell tumors of the ovary. Hum Pathol 1997; 28: 1387-95.
43. Costa MJ, Ames PF, Walls J, Roth LM. Inhibin immunohistochemistry applied to ovarian neoplasms: A novel, effective diagnostic tool. Hum Pathol 1997; 28: 1247-54.
44. Wells M. Making sense of inhibin in ovarian tumours. Histopathology 1998; 32: 81-3.
45. Kommoss F, Oliva E, Bhan AK, Young RH, Scully RE. Inhibin expression in ovarian tumors and tumor-like lesions: An immunohistochemical study. Mod Pathol 1998; 11: 656-64.
46. Yamashita K, Yamoto M, Shikone T et al. Production of inhibin A and inhibin B in human ovarian sex cord stromal tumors. Am J Obstet Gynecol 1997; 177: 1450-7.
47. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol 1998; 29: 840-5.
48. Riopel MA, Perlman EJ, Seidman JD, Kurman RJ, Sherman ME. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcaemic small cell carcinomas. Int J Gynecol Pathol 1998; 17: 46-53.
49. Rishi M, Howard LN, Bratthauer GL, Tavassoli FA. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 1997; 21: 583-9.
50. Flemming P, Wellmann A, Maschek H, Lang H, Georgii A. Monoclonal antibodies against inhibin represent key markers of adult granulosa cell tumors of the ovary even in their metastases. Am J Surg Pathol 1995; 19: 927-33.
51. Pelkey TJ, Frierson HF Jr, Mills SE, Stoler MH. The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol Pathol 1998; 17: 97-105.
52. Guerrieri C, Franlund B, Malmstrom H, Boeryd B. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: A study using inhibin and cytokeratin 7. Int J Gynecol Pathol 1998; 17: 266-71.
53. McCluggage WG, Maxwell P. Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology 2001; 38: 403-8.
54. Doglioni C, Dei Tos AP, Laurino L. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20: 1037-46.
55. Cao QJ, Jones JG, Li M. Expression of calretinin in human ovary, testis and ovarian sex cord-stromal tumors. Int J Gynecol Pathol 2001; 20: 346-52.
56. Deavers MT, Malpica A, Ordonez NG, Silva EG. Ovarian steroid cell tumors: An immu-nohistochemical study including a comparison of calretinin with inhibin. Int J Gynecol Pathol 2003; 22: 162-7.
57. Loo KT, Leung AKF, Chan JKC. Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Histopathology 1995; 27: 388-90.
58. Gordon MD, Corless C, Renshaw AA et al. CD99, keratin and vimentin staining of sex cord-stromal tumors, normal ovary and testis. Mod Pathol 1998; 11: 769-73.
59. Choi YL, Kim HS, Ahn G. Immunoexpression of inhibin alpha subunit, inhibin/activin beta subunit and CD99 in ovarian tumors. Arch Pathol Lab Med 2000; 124: 563-9.
60. Stewart CJR, Nandini CL, Richmond JA. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord tumors. J Clin Pathol 2000; 53: 206-11.
61. Busam KJ, Iversen K, Coplan KA et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1) in adrenocortical and other steroid tumors. Am J Surg Pathol 1998; 22: 57-63.
62. Gustafson ML, Lee MM, Scully RE et al. Mullerian inhibiting substance as a marker for sex-cord tumor. N Engl J Med 1992; 326: 466-71.
63. Silverman LA, Gitelman SE. Immunoreactive inhibin, mullerian inhibiting substance and activin as biochemical markers for juvenile granulosa cell tumors. J Pediatr 1996; 129: 918-21.
64. Bamberger AM, Ivell R, Balvers M. Relaxin-like factor (RLF): A new specific marker for Leydig cells in the ovary. Int J Gynecol Pathol 1998; 18: 163-8.
65. Sasano H, Mason JI, Sasaki E et al. Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary. Int J Gynecol Pathol 1990; 9: 352-62.
66. Costa MJ, Morris R, Sasano H. Sex steroid biosynthesis enzymes in ovarian sex cord-stromal tumors. Int J Gynecol Pathol 1994; 13: 109-19.
67. Tiltman AJ, Ali H. Distribution of alpha glutathione S-transferase in ovarian neoplasms: An immunohistochemical study. Histopathology 2001; 39: 266-72.
68. Tiltman AJ, Haffajee Z. Sclerosing stromal tumors, thecomas and fibromas of the ovary: An immunohistochemical profile. Int J Gynecol Pathol 1999; 18: 254-8.
69. Mouhedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: An immunohistochemical study of 215 cases. Am J Surg Pathol 2002; 26: 1477-83.
70. Shah VI, Freites ON, Maxwell P, McCluggage WG. Inhibin is more specific than calretinin as an immunohistochemical marker for differentiating sarcomatoid granulosa cell tumour of the ovary from other spindle cell neoplasms. J Clin Pathol 2003; 56: 221-4.
71. McCluggage WG, Maxwell P. Adenocarcinomas of various sites may exhibit immuno-reactivity with anti-inhibin antibodies. Histopathology 1999; 35: 216-20.
72. Aquirre P, Thor AD, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors: An immunohistochemical study. Int J Gynecol Pathol 1989; 8: 364-73.
73. Otis CN, Powell JL, Barbuto D et al. Intermediate filamentous proteins in adult granulosa cell tumors. Am J Surg Pathol 1992; 16: 962-8.
74. Czernobilsky B, Moll R, Levy R, Franke WW. Co-expression of cytokeratin and vimentin flaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol 1985; 37: 175-90.
75. Costa MJ, DeRose PB, Roth LM, Brescia RJ, Zaloudek CJ, Cohen C. Immunohistochemical phenotype of ovarian granulosa cell tumors: Absence of epithelial membrane antigen has diagnostic value. Hum Pathol 1994; 25: 60-6.
76. Flemming P, Grothe W, Maschek H, Petry KU, Wellmann A. The site of inhibin production in ovarian neoplasms. Histopathology 1996; 29: 465-8.
77. McCluggage WG. The value of inhibin staining in gynaecological pathology. Int J Gynecol Pathol 2001; 20: 79-85.
78. McCluggage WG, Patterson A, White J, Anderson NH. Immunocytochemical staining of ovarian cyst aspirates with monoclonal antibody against inhibin. Cytopathology 1998; 9: 336-42.
79. Devouassoux-Shisheboran M, Silver SA, Tavassoli FA. Wolffian adnexal tumor, so-called female adnexal tumor of probable Wolffian origin (FATWO): Immunohistochemical evidence in support of a Wolffian origin. Hum Pathol 1999; 30: 856-63.
80. Tiltman AJ, Allard U. Female adnexal tumours of probable Wolffian origin: An immuno-histochemical study comparing tumours, mesonephric remnants and paramesonephric derivatives. Histopathology 2001; 38: 237-42.
81. Clement PB, Scully RE. Uterine tumors resembling ovarian sex cord tumors: A clinico-pathologic analysis of fourteen cases. Am J Clin Pathol 1976; 66: 512-25.
82. Krishnamurthy S, Jungbloth AA, Busam KJ, Rosai J. Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation. Am J Surg Pathol 1998; 22: 1078-82.
83. Baker RJ, Hildebrant RH, Rouse RV, Hendrickson MR, Longacre TA. Inhibin and CD 99 (MIC2) expression in uterine stromal neoplasms with sex cord-like elements. Hum Pathol 1999; 30: 671-9.
84. McCluggage WG. Uterine tumours resembling ovarian sex cord tumours: Immunohisto-chemical evidence for true sex cord differentiation. Histopathology 1999; 34: 373-80.
85. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: Distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26: 1260-7.
86. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995; 19: 417-32.
87. Matias Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569-77.
88. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: Diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000; 24: 797-806.
89. Stewart RL, Royds JA, Burton JL et al. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology 1998; 33: 440-5.
90. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990; 3: 120-8.
91. McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: Report of five cases including two associated with tamoxifen therapy. Hum Pathol 2003; 34: 939-43.
92. Quddus MR, Sung CJ, Zheny W, Lauchlan SC. P53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 1999; 35: 44-9.
93. Schlosshauer PW, Ellenson LH, Soslow RA. B-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002; 15: 1032-7.
94. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinomas: An immunohistochemical study. Int J Gynecol Pathol 2002; 21: 4-10.
95. McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochem-ical stains, including carcinoembryonic antigen, vimentin and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002; 21: 11-15.
96. Kamoi S, Al Juboury MI, Akin MR, Silverberg SG. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: Another viewpoint. Int J Gynecol Pathol 2002; 21: 217-23.
97. Staebler A, Sherman ME, Zaino RJ, Ronnett BM. Hormone receptor immunohistochem-istry and human papilloma virus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 2002; 26: 998-1006.
98. McCluggage WG, Jenkins D. P16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003; 22: 231-5.
99. O'Leary JJ, Landers RJ, Crowley M et al. Human papillomavirus and mixed epithelial tumors of the endometrium. Hum Pathol 1998; 29: 383-9.
100. Oliva E, Young RH, Clement PB, Scully RE. Myxoid and fibrous endometrial stromal tumors of the uterus. A report of 10 cases. Int J Gynecol Pathol 1999; 18: 310-19.
101. Oliva E, Young RH, Clement PB, Bhan AK, Scully RE. Cellular benign mesenchymal tumors of the uterus: A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and seven endometrial stromal nodules, two frequently confused tumors. Am J Surg Pathol 1995; 19: 757-68.
102. Franquemont DW, Frierson HF Jr, Mills SE. An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms: Evidence for smooth muscle differentiation. Am J Surg Pathol 1991; 15: 861-70.
103. Devaney K, Tavassoli FA. Immunohistochemistry as a diagnostic aid in the interpretation of unusual mesenchymal tumors of the uterus. Mod Pathol 1991; 4: 225-31.
104. Farhood AI, Abrams J. Immunohistochemistry of endometrial stromal sarcoma. Hum Pathol 1991; 22: 224-30.
105. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001; 39: 273-8.
106. Chu PG, Arber PA, Weiss LM et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: An immunohistochemical comparison of 34 cases. Mod Pathol 2001; 14: 465-71.
107. Nucci MR, O'Connell JT, Huettner PC et al. H-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 2001; 25: 455-63.
108. Rash DS, Tan JY, Baergen RN et al. H-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol 2001; 25: 253-8.
109. Agoff SN, Grieco VS, Garcia R, Gown AM. Immunohistochemical distinction of endome-trial stromal sarcoma and cellular leiomyoma. Appl Immuno Mol Morphol 2001; 9: 164-9.
110. Toki T, Shimizu M, Takagi Y, Ashida T, Konishi I. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2002; 21: 41-7.
111. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000; 113: 374-82.
112. Scully RE. Smooth muscle differentiation in genital tract disorders. Arch Pathol Lab Med 1981; 105: 505-7.
113. Oliva E, Clement PB, Young RH, Scully RE. Mixed endometrial stromal and smooth muscle tumors of the uterus: A clinicopathologic study of 15 cases. Am J Surg Pathol 1998; 22: 997-1005.
114. Sumathi VP, McCluggage WG. CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol 2002; 25: 391-2.
115. Vang R, Kempson RL. Perivascular epithelioid cell tumor (PEComa) of the uterus: A subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002; 26: 1-13.
116. Silva EG, Deavers MT, Bodurka D, Malpica A. Uterine epithelioid leiomyosarcomas with clear cells or malignant PEComas? Mod Pathol 2003; 16: 211(A).
117. Zamecnik M, Michal M. HMB45p hyalinized epithelioid tumor of the uterus is linked to epithelioid leiomyoma rather than PEC-omas. Int J Surg Pathol 2001; 9: 341-3.
118. McCluggage WG, Walsh MY, Thornton CM et al. Inter and intraobserver variation in the histopathological reporting of cervical squamous intraepithelial lesions using a modified Bethesda grading system. Br J Obstet Gynaecol 1998; 105: 206-10.
119. McCluggage WG, Bharucha H, Date A et al. Interobserver variation in the reporting of cervical colposcopic biopsies. Comparison of grading systems. J Clin Pathol 1996; 49: 833-5.
120. McCluggage WG, Tang L, Maxwell P, Bharucha H. Monoclonal antibody MIB1 in the assessment of cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1996; 15: 131-6.
121. McCluggage WG, Maxwell P, Bharucha H. Immunohistochemical detection of metallo-thionein and MIB1 in uterine cervical squamous lesions. Int J Gynecol Pathol 1998; 17: 29-35.
122. Mittal KR, Demopoulos RI, Goswami S. Proliferating cell nuclear antigen (cyclin) expres-sion in normal and abnormal cervical squamous epithelia. Am J Surg Pathol 1993; 17: 117-22.
123. Raju GC. Expression of the proliferating cell nuclear antigen in cervical neoplasia. Int J Gynecol Pathol 1994; 12: 337-41.
124. Kobayashi I, Matsuo K, Ishibashi Y, Kanda S, Sati H. The proliferative activity in dysplasia and carcinoma in situ of the uterine cervix analysed by proliferating cell nuclear antigen immunostaining and silver-binding argyrophilic nucleolar organiser region staining. Hum Pathol 1994; 25: 198-202.
125. Bulten J, Van der Laak JAWM, Gemmink JH, Pahlplatz MMM, de Wilde PCM, Hanselaar AGJM. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. J Pathol 1996; 178: 268-73.
126. Al-Saleh W, Delvenne P, Greimers R, Fridman P, Doyen J, Boniver J. Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix: Correlation with histological grade and human papilloma virus type. Am J Clin Pathol 1995; 104: 154-60.
127. Payne S, Kernohan NM, Walker F. Proliferation in the normal cervix and in preinvasive cervical lesions. J Clin Pathol 1996; 49: 667-71.
128. Mittal K. Utility of proliferation-associated marker MIB1 in evaluating lesions of the uterine cervix. Adv Anat Pathol 1999; 6: 177-85.
129. Kruse AJ, Baak JPA, Helliesen T, Kjellevold KH, Bol MGW, Janssen EAM. Evaluation of MIB-1 positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1501-7.
130. Mittal K, Mesia A, Demopoulos RI. MIB1 expression is useful in distinguishing dysplasia from atrophy in elderly women. Int J Gynecol Pathol 1999; 18: 122-4.
131. Pirog EC, Baergen RN, Soslow RA et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB1 immunostaining. Am J Surg Pathol 2002; 26: 70-5.
132. Mittal K. Utility of MIB1 in evaluating cauterised cervical cone biopsy margins. Int J Gynecol Pathol 1999; 18: 211-14
133. Keating JT, Cviko A, Riethdorf S et al. Ki-67, cyclin E and p16 (INK4) are complementary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25: 884-91.
134. Klaes R, Friedrich T, Spitkovsky D et al. Over expression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
135. Murphy N, Ring M, Killalea AG et al. P16 INK4A as a marker for cervical dyskaryosis: Cin and CGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003; 56: 56-63.
136. Klaes R, Benner A, Friedrich T et al. P16Ink4A immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1389-99.
137. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neo-plasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002; 41: 313-21.
138. McCluggage WG, Maxwell P, McBride HA, Hamilton PW, Bharucha H. Monoclonal anti-bodies Ki-67 and MIB1 in the distinction of tuboendometrial metaplasia from endocervical adenocarcinoma and adenocarcinoma in situ in formalin fixed material. Int J Gynecol Pathol 1995; 14: 209-16.
139. Van Hoeven KH, Ramondetta L, Kovatich AJ, Bibbo L, Dunton CJ. Quantitative image analysis of MIB1 reactivity in inflammatory, hyperplastic and neoplastic endocervical lesions. Int J Gynecol Pathol 1997; 16: 15-21.
140. Pirog EC, Isacson C, Szabolcs MJ, Kleter B, Quint W, Richart RM. Proliferative activity of benign and neoplastic endocervical epithelium and correlation with HPV DNA detection. Int J Gynecol Pathol 2002; 21: 22-6.
141. Cina SJ, Richardson MS, Austin RM, Kurman RJ. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol 1997; 10: 176-80.
142. McCluggage WG, Maxwell P, Bharucha H. Immunohistochemical detection of p53 and bcl2 proteins, in neoplastic and non-neoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997; 16: 22-7.
143. McCluggage WG, Maxwell P. Bcl-2 and p21 immunostaining of cervical tubo-endometrial metaplasia. Histopathology 2002; 40: 107-8.
144. Piek JMJ, van Diest PJ, Verheijen RHM, Kenemans P. Cell cycle-related proteins p21 and bcl2: Markers of differentiation in the human fallopian tube. Histopathology 2001; 38: 481-2.
145. Henderson GS, Brown KA, Perkins SL, Abbott TM, Clayton F. Bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod Pathol 1996; 9: 430-6.
146. Reithdorf L, Riethdorf S, Lee KR, Cviko A, Loning T, Crum CP. Human papillomavirus, expression of p16 INK4A and early endocervical glandular neoplasia. Hum Pathol 2002; 33: 899-904.
147. Negri G, Egarter-Vigli E, Kasal A, Romano F, Haitel A, Mian C. P16 INK4A is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: An immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003; 27: 187-93.
148. Marques T, Andrade LA, Vassallo J. Endocervical tubal metaplasia and adenocarcinoma in situ: Role of immunohistochemistry for carcinoembryonic antigen and vimentin in differential diagnosis. Histopathology 1996; 28: 549-50.
149. Gilks CB, Young RH, Aquirre P et al. Adenoma malignum/minimal deviation adenocar-cinoma of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. Am J Surg Pathol 1989; 13: 717-29.
150. Michael H, Grave L, Kraus FT. Minimal deviation endocervical adenocarcinoma: Clinical and histologic features, immunohistochemical staining for carcinoembryonic antigen and differentiation from confusing benign lesions. Int J Gynecol Pathol 1984; 3: 261-76.
151. Ordi J, Romagosa C, Tavassoli FA et al. CD10 expression in epithelial tissues and tumors of the gynaecologic tract: A useful marker in the diagnosis of mesonephric, trophoblastic and clear cell tumors. Am J Surg Pathol 2003; 27: 178-86.
152. Ordi J, Nogales FF, Palacia A et al. Mesonephric adenocarcinoma of the uterine corpus: Cd10 expression as evidence of mesonephric differentiation. Am J Surg Pathol 2001; 25: 1540-5.
153. McCluggage WG, Oliva E, Herrington CS, McBride H, Young RH. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: Cd10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology 2003; 43: 144-50.
154. Nascimento AF, Hirsch MS, Cviko A, Quade BJ, Nucci MR. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis. Mod Pathol 2003; 16: 22-7.
155. Ishii K, Kumagai T, Tozuka M, Ota H, Katsuyama T, Kurihara M. A new diagnostic method for adenoma malignum and related lesions: Latex aglutination test with a new monoclonal antibody, HIK 1083. Clinica Chimica Acta 2001; 312: 231-3.
156. Ischimura T, Koizumi T, Tateiwa H et al. Immunohistochemical expression of gastric mucin and p53 in minimal deviation adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 2001; 20: 220-6.
157. Utsugi K, Hirai Y, Takeshima N, Akiyama F, Sakurai S, Hasumi K. Utility of the monoclonal antibody HIK1083 in the diagnosis of adenoma malignum of the uterine cervix. Gynecol Oncol 1999; 75: 345-8.
158. Nucci MR, Clement PB, Young RH. Lobular endocervical glandular hyperplasia, not otherwise specific: A clinicopathologic analysis of thirteen cases of a distinctive pseudo-neoplastic lesion and comparison with fourteen cases of adenoma malignum. Am J Surg Pathol 1999; 23: 886-91.
159. Mikami Y, Hata S, Melamed J, Fujiwara K, Manabe T. Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype. Histopathology 2001; 39: 364-72.
160. McCluggage WG, Ashe P, McBride H, Maxwell P, Sloan JM. Localisation of the cellular expression of inhibin in trophoblastic tissue. Histopathology 1998; 32: 252-6.
161. Kommoss F, Schmidt D, Coerdt W, Olert J, Munteferig H. Immunohistochemical expression analysis of inhibin-alpha and-beta subunits in partial and complete moles, trophoblastic tumors and endometrial decidua. Int J Gynecol Pathol 2001; 20: 380-5.
162. Shih IM, Seidman JD, Kurman RJ. Placental site nodule and characterisation of distinctive types of intermediate trophoblast. Hum Pathol 1999; 30: 687-94.
163. Shih IM, Kurman RJ. Immunohistochemical localisation of inhibin-alpha in the placenta and gestational trophoblastic lesions. Int J Gynecol Pathol 1999; 18: 144-50.
164. Pelkey TJ, Frierson HF, Mills SE, Stoler MH. Detection of the alpha-subunit of inhibin in trophoblastic neoplasia. Hum Pathol 1999; 30: 26-31.
165. Shih IM, Kurman RJ. Epithelioid trophoblastic tumor-a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 1998; 22: 1393-403.
166. Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001; 20: 31-47.
167. Shih IM, Kurman RJ. Ki-67 labelling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor and choriocarcinoma. A double immunohistochemical staining technique using Ki-67 and mel CAM antibodies. Hum Pathol 1998; 29: 27-33.
168. Singer G, Kurman RJ, McMaster MT, Shih IM. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002; 26: 914-20.
169. Castrillon DH, Sun DQ, Weremowicz S, Fisher RA, Crum CP, Genest DR. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57 (KIP2). Am J Surg Pathol 2001; 25: 1225-30.
170. Fukunaga M. Immunohistochemical characterization of p57KIP2 expression in early hydatidiform moles. Hum Pathol 2002; 33: 1188-92.
171. Nucci MR, Fletcher CDM. Vulvovaginal soft tissue tumours: Update and review. Histopathology 2000; 36: 97-108.
172. McCluggage WG, Patterson A, Maxwell P. Aggressive angiomyxoma of pelvic parts exhibits oestrogen and progesterone receptor postivity. J Clin Pathol 2000; 53: 603-5.
173. Hartmann CA, Sperling M, Stein H. So-called fibroepithelial polyps of the vagina exhibit-ing an unusual but uniform antigen profile characterised by expression of desmin and steroid hormone receptors but no muscle-specific actin or macrophages markers. Am J Clin Pathol 1990; 93: 604-8.
174. Nielsen GP, Rosenberg AE, Young RH, Lee KC, Chan JKC. Angiomyofibroblastoma of the vulva and vagina. Mod Pathol 1996; 9: 284-91.
175. Nucci MR, Weremowicz S, Neskey DM et al. Chromosomal translocation t(8; 12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. Genes Chrom Can 2001; 32: 172-6.
176. Nucci MR, Tallini G, Quade BJ. HMGIC expression as a diagnostic marker for vulvar aggressive angiomyxoma. Mod Pathol 2001; 14: 829(A).
177. Lloyd J, Flanaghan AM. Mammary and extramammary Paget's disease. J Clin Pathol 2000; 53: 742-9.
178. Goldblum JR, Wart WR. Vulvar Paget's disease: A clinicopathologic and immunohisto-chemical study of 19 cases. Am J Surg Pathol 1997; 21: 1178-87.
179. Goldblum JR, Hart WR. Perianal Paget's disease-a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol 1998; 2: 170-9.
180. Crawford D, Nimmo M, Clement PB et al. Prognostic factors in Paget's disease of the vulva: A study of 21 cases. Int J Gynecol Pathol 1999; 18: 351-9.
181. Brainard JA, Hart WR. Proliferative epidermal lesions associated with anogenital Paget's disease. Am J Surg Pathol 2000; 24: 543-52.
182. Fox H, Wells M. Recent advances in pathology of the vulva. Histopathology 2003; 42: 209-16.
183. Raju RR, Goldblum JR, Hart WR. Pagetoid squamous cell carcinoma in situ (Pagetoid Bowen's disease) of the external genitalia. Int J Gynecol Pathol 2003; 22: 127-35.
184. Brown HM, Wilkinson EJ. Uroplakin III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum Pathol 2002; 33: 545-8.